Market News AIOpen the app

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

TrialRead the original at Benzinga
Good for ABT

Abbott reported 96.3% complete closure with Amulet 360 and 97% procedural success with SonicForce. These results support its device prospects, but both devices are still investigational.

ABT · Abbott Laboratories

AI read · Good for ABT

The AI's read

The results give Abbott encouraging evidence that two heart devices worked in the patients they were designed to help. That may support their future use. Both devices are still described as investigational, so the results do not establish approved use or sales.

Get alerts for ABT

Follow Abbott Laboratories (ABT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ABT
Free on the App Store and Google Play, or on the web.